Tadalafil 171596-29-5 tractare erectile Dysfunction in homines
Product Detail
| Nomen | Tadalafil |
| Cas numerum | 171596-29-5 |
| MOLECULA | C22h19n3o4 |
| Pondus | 389,4 |
| Einecs numerum | 687-782-2 |
| Specifica gyrationis | D20 + 71.0 ° |
| Densitas | 1.51 ± 0.1g / CM3 (praedicta) |
| Repono condicionem | 2-8 ° C |
| Forma | Pulverem |
| Acetosum coefficientem | (Pka) 16.68 ± 0.40 (praedicta) |
| Aqua Solubility | DMSO: solutum 20mg / ml, |
Synonyma
Tadalafil; Cialis; IC 351;(6R,12AR)-6-(benzo[d][1,3]dioxol-5-yl)-2-methyl-2,3,12,12a-tetrahydropyrazino[1',2':1,6]pyrido;GF 196960;ICOS 351;Tildenafil;
Pharmacological effectus
Tadalafil (Tadalafil, Tadalafil) habet mocecular formula c22h19n3o4 et molecular pondus 389,4. Hoc est late usus est in curatio masculus erectile dysfunction quia MMIII, cum commercia nomen cialis (cialis). In June MMIX, in FDA probatus Tadalafil in Civitatibus Foederatis Americae Treatment of aegris cum pulmonis arteriis hypertension (Pah) in commercia nomen Adcoirca. Tadalafil introducta in MMIII sicut medicamento ad curatio ed. It takes effectum XXX minuta post administrationem, sed optimum effectum est 2h post impetu actionis, et effectus potest durare ad 36h, et effectus non affectus cibum. Dose of Tadalafil est X aut XX mg, commendatur initial dose est X mg et dose est adaequatum secundum patientes estote responsio et adversa reactiones. Pre-foro studiis ostensum est quod post oris administratione X vel XX mg de Tadalafil enim XII weeks, quod effective rates sunt LXVII% et LXXXI%, respective. Multi studiis ostensum est quod Tadalafil est melius efficaciam in curatio ed.
Erectile Dysfunction: Tadalafil est selectivam phosphodiesterase Type V (Pde5) sicut Sildenafil, sed ejus structuram est aliud ab hoc, et summus adipem victu non intermixti cum suis effusio. Sub actione sexualem excitanda, nitric cadmiae synthase (n) in Penore nervi exitus et vascularium endothelial cellulis Catalyzes in synthesis nitric cadmiae (no) a subiecto nitricis (non) a subiecto nitricis. Non actuat Guanylate Cyclase, quod converts Guanosine triphosphate ad Cyclic Guanosine Monophosphate (CGMP), ita activum Cyclic guanosine monophosphate-dependens dapibus ions in lenis musculus in concentratione calcium ions in lenis musculus cellulis, causando calcium musculus erection ex causa ad relaxationem muscle Phosphodiesterase Type V (PDE5) Degredes CGMP in sedentes products, faciens penis in infirmi status. Tadalafil inhibits degradation PDE5, ducens ad cumulus CGMP, quod resolvit lenis musculus Corpus Cavernosum, ducens ad Penile erectione. Quia nitrates non oblatorum, combined usu cum Tadalafil et significantly crescat campester of CGMP et ducunt ad gravibus hypotension. Unde et coniuncta usum duo contraindicated in orci usu.
Tadalafil operatur inhibere Pdes. GMP est degradatus, sic combined usum cum nitrates, ut faciam in extrema gutta in sanguine pressura et auget periculo Syncope. CY3PA4 inducers will reduce the bioavailability of tadanafil, and the combination with rifampicin, cimetidine, erythromycin, clarithromycin, itracon, ketocon, and HVI protease inhibitors may increase the The blood concentration of the drug should be adjusted. Ita procul, sunt non refert, ut pharmacokinetic parametri huius productum sunt affectus victu et alcohol.
